

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5598794

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DAVID J. LIVINGSTON	09/13/2018
ANDREW CARR	08/24/2018
PHILIPPE FERNANDES	08/05/2018
RECEIVING PARTY DATA	
Name:	METROBIOTECH, LLC
Street Address:	540 HAWTHORNE STREET
City:	BIRMINGHAM
State/Country:	MICHIGAN
Postal Code:	48009
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16454457
CORRESPONDENCE DATA	
Fax Number:	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 832-1728
Email:	patentdocketing@foleyhoag.com, rcc@foleyhoag.com
Correspondent Name:	FOLEY HOAG LLP
Address Line 1:	155 SEAPORT BLVD., SEAPORT WEST
Address Line 4:	BOSTON, MASSACHUSETTS 02210-2600
ATTORNEY DOCKET NUMBER:	MBS-00104
NAME OF SUBMITTER:	GRETCHEN S. PETERSON
SIGNATURE:	/Gretchen S. Peterson/
DATE SIGNED:	07/01/2019
Total Attachments: 9	
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page1.tif	
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page2.tif	
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page3.tif	
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page4.tif	

source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page5.tif
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page6.tif
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page7.tif
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page8.tif
source=MBS00104_Executed_Inventors_Assignment_to_MetroBiotech_LLC#page9.tif

ASSIGNMENT

WHEREAS we, **ANDREW CARR, PHILIPPE FERNANDES and DAVID J. LIVINGSTON** have invented one or more inventions described in an application for Letters Patent of the United States, entitled **CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE** the specification of which:

☐ is being executed on even date herewith; and is about to be filed in the United States Patent Office;

☒ was filed on September 30, 2016 as Application No. PCT/US16/054776;

☒ was filed on April 2, 2018 as Application No. 15/765,325;

☐ was patented under U.S. Patent No. _____ on _____


WHEREAS **MetroBiotech, LLC**, (hereinafter "ASSIGNEE"), having principal offices at **540 Hawthorne Street, Birmingham, Michigan 48009**, desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention(s) as described in said application, together with our entire right, title and interest in and to said application and such Letters Patent as may issue thereon, and any substitution, reissue, continuation, divisional, revival and foreign counterparts thereof and including the right to claim priority under any applicable statute, treaty or convention based on said application; said invention(s), application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, all choses in action pertaining to the applications or Letters Patent including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications or Letters Patent. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

B4819186.1

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of substitution, reissue, divisional, continuation or revival applications and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention(s) or any application or patent directed thereto may be involved;

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

Inventor:  Date: 24th Aug 2018
Andrew Carr

Address: ~~91 Lancaster Gate~~ 21 NORTHEND ROAD AC
~~Cambridge CB236AU~~ WIXTON
~~United Kingdom~~ CB10 1RE, UNITED KINGDOM

Witness: Susan Osbourn Date: 24th August 2018

Print Name: SUSAN OSBOURN

Address: 24 GUNSON GATE, CHELMSFORD, ESSEX
CH2 9NZ

Atty. Docket No.: MBS-00101

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of MetroBiotech, LLC,

By: Eric M. Livak Hale

Date: 8/24/2018

Name: Eric M. Livak Hale

Title: Innovation Manager

- 5 -

B4019186.1

ASSIGNMENT

WHEREAS we, **ANDREW CARR, PHILIPPE FERNANDES** and **DAVID J. LIVINGSTON** have invented one or more inventions described in an application for Letters Patent of the United States, entitled **CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE** the specification of which:

☐ is being executed on even date herewith; and is about to be filed in the United States Patent Office;

☒ was filed on September 30, 2016 as Application No. PCT/US16/054776;

☒ was filed on April 2, 2018 as Application No. 15/765,325;

☐ was patented under U.S. Patent No. _____ on _____

WHEREAS **MetroBiotech, LLC**, (hereinafter "ASSIGNEE"), having principal offices at **540 Hawthorne Street, Birmingham, Michigan 48009**, desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention(s) as described in said application, together with our entire right, title and interest in and to said application and such Letters Patent as may issue thereon, and any substitution, reissue, continuation, divisional, revival and foreign counterparts thereof and including the right to claim priority under any applicable statute, treaty or convention based on said application; said invention(s), application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, all choses in action pertaining to the applications or Letters Patent including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications or Letters Patent. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

B4819186.1

Inventor:  Date: 05 Aug 18
Philippe Fernandes

Address: ~~19 Monmouth Drive~~ PE 23 Busk
~~Cambridge CB4 1JL~~ 05 AUG 18 Grok Markt
~~United Kingdom~~ 2300 Turnhout
Belgium

Print name: Melina Heinrich-Fernandes Date: 05 AUG 2018
Witness:

Signature: 
Print Name:

Address: 23 Grok Markt Bus 4, 2300 Turnhout, Belgium

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of MetroBiotech, LLC,

By: Eric M. Livak Hale Date: 8/6/2018

Name: Eric M. Livak Hale

Title: Innovation Manager

ASSIGNMENT

WHEREAS we, **ANDREW CARR, PHILIPPE FERNANDES and DAVID J. LIVINGSTON** have invented one or more inventions described in an application for Letters Patent of the United States, entitled **CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE** the specification of which:

☐ is being executed on even date herewith; and is about to be filed in the United States Patent Office;

☒ was filed on September 30, 2016 as Application No. PCT/US16/054776;

☒ was filed on April 2, 2018 as Application No. 15/765,325;

☐ was patented under U.S. Patent No. _____ on _____

WHEREAS **MetroBiotech, LLC**, (hereinafter "ASSIGNEE"), having principal offices at **540 Hawthorne Street, Birmingham, Michigan 48009**, desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention(s) as described in said application, together with our entire right, title and interest in and to said application and such Letters Patent as may issue thereon, and any substitution, reissue, continuation, divisional, revival and foreign counterparts thereof and including the right to claim priority under any applicable statute, treaty or convention based on said application; said invention(s), application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, all choses in action pertaining to the applications or Letters Patent including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications or Letters Patent. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

Inventor: David J. Livingston Date: Sept. 13, 2018
David J. Livingston

Address: **52 Jennys Lane**
Barrington, RI 02806

Witness: Michael Willis Date: Sept. 13, 2018

Print Name: Michael Willis

Address: c/o Metro International Biotek, LLC
100 Barber Avenue, Worcester MA 01605

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of **MetroBiotech, LLC**,

By: *Eric M. Livak Hale* Date: 9/13/2018

Name: Eric M. Livak Hale

Title: Innovation Manager